T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan plc
AGN
|
+$2.6B |
| 2 |
BNY
Bank of New York Mellon
BNY
|
+$1.1B |
| 3 |
Elevance Health
ELV
|
+$903M |
| 4 |
DD
Du Pont De Nemours E I
DD
|
+$873M |
| 5 |
Medtronic
MDT
|
+$868M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan Inc
AGN
|
+$3.89B |
| 2 |
COV
COVIDIEN PLC COM SHS NEW (IRELAND)
COV
|
+$1.06B |
| 3 |
CFN
CAREFUSION CORPORATION
CFN
|
+$946M |
| 4 |
Aptiv
APTV
|
+$886M |
| 5 |
KSU
Kansas City Southern
KSU
|
+$662M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 21.05% |
| 2 | Consumer Discretionary | 13.82% |
| 3 | Financials | 13.14% |
| 4 | Industrials | 11.9% |
| 5 | Technology | 9.68% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Alphabet (Google) Class C
GOOG
$4.49T
| $10.3B | 2.13% |
375,340,015
-2,320,974
| -0.6% | -$62.2M |
|
2
Amazon
AMZN
$3.07T
| $8.12B | 1.68% |
436,691,900
-22,329,900
| -5% | -$393M |
|
3
Danaher
DHR
$138B
| $6.52B | 1.35% |
114,220,215
+1,019,367
| +0.9% | +$58.5M |
|
4
Apple
AAPL
$4.5T
| $6.24B | 1.29% |
200,451,848
+12,232,032
| +6% | +$369M |
|
5
Visa
V
$687B
| $5.94B | 1.23% |
90,834,977
-8,629,059
| -9% | -$571M |
|
|
AGN
6
DELISTED
Allergan plc
AGN
| $5.89B | 1.22% |
19,774,223
+9,136,305
| +86% | +$2.6B |
|
7
Booking.com
BKNG
$149B
| $5.88B | 1.21% |
126,281,925
+46,000
| +0% | +$2.06M |
|
8
Boeing
BA
$180B
| $5.87B | 1.21% |
39,094,785
-32,327
| -0.1% | -$4.71M |
|
9
McKesson
MCK
$100B
| $5.17B | 1.07% |
22,861,308
+201,641
| +0.9% | +$44.7M |
|
10
Meta Platforms (Facebook)
META
$1.49T
| $4.88B | 1.01% |
59,321,443
+3,422,410
| +6% | +$268M |
|
11
American Airlines Group
AAL
$10.8B
| $4.63B | 0.96% |
87,794,460
-2,372,581
| -3% | -$120M |
|
12
Gilead Sciences
GILD
$161B
| $4.6B | 0.95% |
46,849,573
-4,751,945
| -9% | -$483M |
|
13
Biogen
BIIB
$29.9B
| $4.56B | 0.94% |
10,791,562
-1,384,986
| -11% | -$546M |
|
14
Baidu
BIDU
$38.3B
| $4.09B | 0.84% |
19,617,871
+80,858
| +0.4% | +$17.3M |
|
15
JPMorgan Chase
JPM
$941B
| $4.08B | 0.84% |
67,386,767
+3,632,579
| +6% | +$215M |
|
16
Bausch Health
BHC
$2.52B
| $4B | 0.83% |
20,125,336
+2,283,052
| +13% | +$405M |
|
17
GE Aerospace
GE
$381B
| $3.88B | 0.8% |
32,664,563
+1,768,018
| +6% | +$210M |
|
|
ALXN
18
DELISTED
Alexion Pharmaceuticals
ALXN
| $3.83B | 0.79% |
22,075,126
+1,899,735
| +9% | +$344M |
|
19
Lowe's Companies
LOW
$117B
| $3.72B | 0.77% |
49,989,824
-6,028,382
| -11% | -$432M |
|
20
UnitedHealth
UNH
$377B
| $3.62B | 0.75% |
30,576,807
+619,189
| +2% | +$68.8M |
|
21
Morgan Stanley
MS
$331B
| $3.39B | 0.7% |
95,044,521
+8,670,525
| +10% | +$311M |
|
|
CELG
22
DELISTED
Celgene Corp
CELG
| $3.2B | 0.66% |
27,769,120
+744,643
| +3% | +$89M |
|
23
Mastercard
MA
$503B
| $3.07B | 0.63% |
35,509,332
+802,964
| +2% | +$69.7M |
|
24
Pfizer
PFE
$142B
| $3.07B | 0.63% |
92,862,414
+189,665
| +0.2% | +$6.03M |
|
|
MRSH
25
Marsh
MRSH
$91.6B
| $3.04B | 0.63% |
54,202,488
+4,145,061
| +8% | +$234M |
|
Similar funds
T. Rowe Price Associates's Q1 2015 Portfolio in Review
As of Q1 2015, T. Rowe Price Associates held 2,630 positions worth $484B, up 2.8% from $471B the previous quarter. Its ten largest holdings account for 13% of the portfolio.
T. Rowe Price Associates's Q1 2015 filing shows 93 new, 1,078 increased, 887 reduced and 93 closed positions. Its largest new stake was ACTAVIS PLC Pfd Conv Ser A (Irl): 516,600 shares worth $532M. The largest sale was Allergan Inc, an estimated $3.89B.
By sector, the portfolio is most concentrated in Healthcare at 21% of assets, up from 20% a quarter earlier, followed by Consumer Discretionary and Financials.
- T. Rowe Price Associates's largest Q1 2015 buy was ACTAVIS PLC Pfd Conv Ser A (Irl): 516,600 shares worth $532M.
- T. Rowe Price Associates added most to Allergan plc in Q1 2015, an estimated $2.6B increase.
- T. Rowe Price Associates's biggest Q1 2015 reduction was Aptiv, cutting an estimated $886M.
- T. Rowe Price Associates fully exited Allergan Inc in Q1 2015, selling an estimated $3.89B.
- T. Rowe Price Associates's ten largest holdings make up 13% of its $484B portfolio in Q1 2015.
- T. Rowe Price Associates opened 93 new positions and closed 93 in Q1 2015.
- T. Rowe Price Associates's portfolio value rose 2.8% quarter-over-quarter to $484B.
Based on T. Rowe Price Associates's 13F filing for Q1 2015, filed 15 May 2015.